Core Viewpoint - Kymera Therapeutics (KYMR.US) experienced a significant stock surge of over 40%, reaching a historic high of $95.66, following positive results from the expanded Phase 1b trial of its drug KT-621 for atopic dermatitis (AD) [1] Group 1: Trial Results - KT-621 demonstrated deep STAT6 degradation in both the 100 mg and 200 mg dosage groups, with median degradation rates of 94% in skin and 98% in blood, indicating strong translational capability from healthy volunteers to AD patients [1] - The drug showed significant reductions in disease-related type 2 biomarkers in blood, including a 74% median decrease in thymus-activated chemokine (TARC) levels compared to baseline levels in patients similar to those in the dupilumab AD study [1] - Other biomarkers such as Eotaxin-3, IL-31, IgE, and core type 2 inflammation-related gene sets in skin lesions also exhibited notable decreases [1] Group 2: Future Trials - The ongoing Phase 2b BROADEN2 trial for moderate to severe AD is expected to yield data by mid-2027 [1] - A Phase 2b BREADTH trial targeting moderate to severe asthma patients is planned to commence in the first quarter of 2026 [1]